N. Yamamura et al., Evaluation of radioiodinated medium chain fatty acids as new diagnostic agents for the determination of hepatic viability, EUR J NUCL, 26(12), 1999, pp. 1597-1605
Citations number
23
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Medical Research Diagnosis & Treatment
Radiopharmaceuticals which reflect beta-oxidation in hepatocytes will provi
de useful information on the prognosis after surgery or on the efficacy of
treatment, since beta-oxidation is the main pathway responsible for adenosi
ne triphosphate in hepatocytes. We have previously developed [I-C-11]octano
ate as a diagnostic agent for determination of hepatic viability by means o
f positron emission tomography (PET), The goal of the present study was to
develop a new radiopharmaceutical for single-photon emission tomography (SP
ET), which has the advantage of being more widely used than PET. To this en
d, two radioiodinated omega-(4-iodophenyl)-medium chain fatty acids, p-iodo
phenylvaleric acid (IPVA) and p-iodophenylenanthic acid (IPEA), were synthe
sized and evaluated as radiopharmaceuticals for determination of hepatic vi
ability. Metabolite analyses in vitro and in vivo and a biodistribution stu
dy in normal mice indicated that both compounds were taken up by the liver
actively and metabolized by beta-oxidation. However, these studies also ind
icated that IPEA is more suitable as an imaging agent than IPVA. Based on t
hese results, SPET imaging studies were performed in normal and hepatitis m
odel rats using [I-123]IPEA. The time-activity curves of the liver showed t
wo-phase clearance of radioactivity in both normal and hepatitis model rats
, but the clearance was delayed depending on the severity of hepatitis. Fur
thermore, the clearance rate of the first phase was correlated with the ATP
level in hepatocytes, which was used as an index of the energy production
capacity of hepatocytes. In conclusion, IPEA was metabolized predominantly
by beta-oxidation, and the clearance of IPEA from the liver was closely ass
ociated with the ATP concentration in the liver. Thus, [I-123]IPEA is a pot
entially useful new radiopharmaceutical for diagnosis of hepatic viability
based on energy metabolism.